Skip to main content
Article thumbnail
Location of Repository

MMP-10 is overexpressed, proteolytically active and a potential target for therapeutic intervention in human lung carcinomas

By Jason H. Gill, Ian G. Kirwan, Jill M. Seargent, Sandie W. Martin, S. Tijani, V.A. Anikin, A.J. Mearns, Michael C. Bibby, Alan Anthoney and Paul M. Loadman


NoMatrix metalloproteinase (MMP)-mediated degradation of the extracellular matrix is a major factor for tumor development and expansion. This study analysed MMP-10 protein expression and activity in human lung tumors of various grade, stage, and type to address the relationship between MMP-10 and tumor characteristics and to evaluate MMP-10 as a therapeutic target in non small cell lung carcinoma (NSCLC). Unlike the majority of MMPs, MMP-10 was located in the tumor mass as opposed to tumor stroma. MMP-10 protein was observed at low levels in normal human lung tissues and at significantly higher levels in all types of NSCLC. No correlation was observed between MMP-10 protein expression and tumor type, stage, or lymph node invasion. To discriminate between active and inactive forms of MMP-10 in samples of human NSCLC, we have developed an ex vivo fluorescent assay. Measurable MMP-10 activity was detected in 42 of 50 specimens of lung cancer and only 2 of 10 specimens of histologically normal lung tissue. No relationship was observed between MMP-10 activity levels and clinicopathologic characteristics. Our results suggest that MMP-10 is expressed and active at high levels in human NSCLC compared to normal lung tissues, and, as such, is a potential target for the development of novel therapeutics for lung cancer treatment

Topics: Tumour Markers, Heterologous, Transplantation, Animals, Carcinoma, Cell Lline, Tumour, Enzyme Activation, Immunohistochemistry, Lung Neoplasms, Humans, Matrix Metalloproteinase 10, Metalloendopeptidases, Mice, Biological Analysis
Year: 2004
DOI identifier: 10.1593/neo.04283
OAI identifier:
Provided by: Bradford Scholars

Suggested articles


  1. (1999). Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/stromelysin-1 cascade enhances tumor cell invasion. doi
  2. (1998). Activation of the precursor of human stromelysin 2 and its interactions with other matrix metalloproteinases. doi
  3. (1997). Association of expression of metalloproteinases and their inhibitors with the metastatic potential of squamous-cell lung carcinomas. A molecular and immunohistochemical study. doi
  4. (2000). Biological and clinical relevance of doi
  5. (2000). Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. doi
  6. (2004). Differential expression of matrilysin-1 (MMP-7), 92 kD gelatinase (MMP-9), and metalloelastase (MMP-12) in oral verrucous and squamous cell cancer. doi
  7. (2001). Differential patterns of stromelysin-2 (MMP-10) and MT1-MMP (MMP-14) expression in epithelial skin cancers.
  8. (1994). Distinct populations of basal keratinocytes express stromelysin-1 and stromelysin-2 in chronic wounds. doi
  9. (1991). Expression of collagenase-related metalloproteinase genes in human lung or head and neck tumours. doi
  10. (2001). Expression of matrix metalloproteinases and their inhibitors correlates with invasion and metastasis in squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg doi
  11. (1999). Expression of the laminin gamma2 chain in different histological types of lung carcinoma. A study by immunohistochemistry and in situ hybridization. doi
  12. (2003). Extracellular matrix remodelling: the role of matrix metalloproteinases. doi
  13. (2003). Human and mouse proteases: a comparative genomic approach. doi
  14. (1995). Human stromelysins 1 and 2. doi
  15. (2001). Increased expression of laminin-5 and its prognostic significance in lung adenocarcinomas of small size. An immunohistochemical analysis of 102 cases. doi
  16. (2001). Invasion and metastasis: the expression and significance of matrix metalloproteinases in carcinomas of the lung.
  17. (2001). Matrix metalloproteinases in cancer invasion, metastasis and angiogenesis. doi
  18. (2002). Matrix metalloproteinases in cancer: prognostic markers and therapeutic targets. doi
  19. (2000). Matrix metalloproteinases in tumor invasion and metastasis. doi
  20. (1999). Mechanisms for pro matrix metalloproteinase activation. doi
  21. (2000). Metalloproteinases: role in breast carcinogenesis, invasion and metastasis.
  22. (2003). MMP expression profiling in recurred stage IB lung cancer. doi
  23. (2002). Molecular determinants of metalloproteinase substrate specificity: matrix metalloproteinase substrate binding domains, modules, and exosites. doi
  24. (2002). New functions for the matrix metalloproteinases in cancer progression. doi
  25. (2000). Overexpression level of stromelysin 3 is related to the lymph node involvement in non-small cell lung cancer.
  26. (2001). Overexpression of matrix metalloproteinase-10 and matrix metalloproteinase-3 in human diabetic corneas: a possible mechanism of basement membrane and integrin alterations. doi
  27. (1996). Patterns of matrix metalloproteinase and TIMP-1 expression in chronic and normally healing human cutaneous wounds. doi
  28. (2002). Strategies for MMP inhibition in cancer: innovations for the post-trial era. doi
  29. (1998). Stromelysin-1 (MMP-3) and stromelysin-2 (MMP-10) expression in developing human bone: potential roles in skeletal development. doi
  30. (2000). Stromelysin-2 is upregulated during normal wound repair and is induced by cytokines. doi
  31. (2004). Stromelysin-2 overexpression in human esophageal squamous cell carcinoma: potential clinical implications. doi
  32. (1996). Urokinase plasminogen activator as a predictor of aggressive disease in breast cancer. doi
  33. (1998). Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node–negative disease. doi

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.